Eylea® hd (aflibercept) injection 8 mg presentations at arvo reinforce sustained and clinically meaningful outcomes in serious retinal diseases

Long-term data and subgroup analyses from pivotal eylea hd clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseases long-term data and subgroup analyses from pivotal eylea hd clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseases
REGN Ratings Summary
REGN Quant Ranking